ZimVie to be acquired by ARCHIMED for $19.00 per share in cash

ZimVie (ZIMV) announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED. Under the terms of the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share of ZimVie common stock outstanding at the closing of the transaction, corresponding to an enterprise value of approximately $730M. The per share price represents a premium of 99% to the ZimVie 90-day volume-weighted average price of $9.57 per share. The Board of Directors of ZimVie has unanimously approved the transaction. The transaction is expected to close by year-end 2025, subject to the satisfaction of customary closing conditions, including approval by ZimVie’s stockholders and applicable regulatory approvals. The transaction is not subject to a financing condition. Prior to the deal’s closing, ZimVie is operating business as usual, separately from ARCHIMED. Upon completion of the transaction, ZimVie will become a privately held company and ZimVie’s shares will no longer be listed on the NASDAQ stock exchange. Under the terms of the merger agreement, ZimVie, with the assistance of Centerview Partners, its financial advisor, may solicit proposals from third parties for a period of 40 days continuing through midnight, New York City time, on August 29, 2025. ZimVie does not anticipate disclosing any developments regarding this process unless and until its Board of Directors makes a decision with respect to a potential superior proposal. There can be no assurance that the solicitation process will result in a superior proposal.